Teton Advisors Inc. Sells 500 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Teton Advisors Inc. lessened its holdings in Mesa Laboratories, Inc. (NASDAQ:MLABGet Rating) by 9.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,000 shares of the medical instruments supplier’s stock after selling 500 shares during the quarter. Teton Advisors Inc. owned about 0.10% of Mesa Laboratories worth $1,274,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in MLAB. Advisor Group Holdings Inc. lifted its position in Mesa Laboratories by 14.9% during the fourth quarter. Advisor Group Holdings Inc. now owns 1,285 shares of the medical instruments supplier’s stock valued at $422,000 after purchasing an additional 167 shares during the period. First Republic Investment Management Inc. bought a new position in Mesa Laboratories in the fourth quarter worth approximately $381,000. Dimensional Fund Advisors LP raised its position in Mesa Laboratories by 28.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 57,988 shares of the medical instruments supplier’s stock worth $19,026,000 after acquiring an additional 12,894 shares during the period. Teacher Retirement System of Texas raised its position in Mesa Laboratories by 21.1% in the fourth quarter. Teacher Retirement System of Texas now owns 999 shares of the medical instruments supplier’s stock worth $328,000 after acquiring an additional 174 shares during the period. Finally, Citigroup Inc. raised its position in shares of Mesa Laboratories by 40.5% during the 4th quarter. Citigroup Inc. now owns 4,572 shares of the medical instruments supplier’s stock valued at $1,499,000 after purchasing an additional 1,318 shares during the period. Hedge funds and other institutional investors own 92.70% of the company’s stock.

Mesa Laboratories Stock Performance

MLAB opened at $160.34 on Wednesday. Mesa Laboratories, Inc. has a fifty-two week low of $155.53 and a fifty-two week high of $333.42. The stock has a market capitalization of $852.53 million, a price-to-earnings ratio of -534.45 and a beta of 0.58. The company has a fifty day moving average of $190.40 and a 200 day moving average of $215.07. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.29 and a current ratio of 2.90.

Mesa Laboratories (NASDAQ:MLABGet Rating) last released its quarterly earnings results on Thursday, August 4th. The medical instruments supplier reported $0.52 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($1.05). Mesa Laboratories had a positive return on equity of 5.80% and a negative net margin of 0.78%. The firm had revenue of $50.45 million for the quarter, compared to analysts’ expectations of $52.63 million. As a group, sell-side analysts forecast that Mesa Laboratories, Inc. will post 5.26 earnings per share for the current fiscal year.

Mesa Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 15th. Investors of record on Wednesday, August 31st will be issued a dividend of $0.16 per share. The ex-dividend date is Tuesday, August 30th. This represents a $0.64 dividend on an annualized basis and a yield of 0.40%. Mesa Laboratories’s payout ratio is -213.33%.

Insider Activity at Mesa Laboratories

In related news, SVP Brian David Archbold sold 392 shares of Mesa Laboratories stock in a transaction dated Tuesday, June 21st. The shares were sold at an average price of $188.22, for a total transaction of $73,782.24. Following the completion of the sale, the senior vice president now owns 813 shares in the company, valued at approximately $153,022.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Mesa Laboratories news, Director Evan Guillemin sold 3,692 shares of the business’s stock in a transaction that occurred on Thursday, August 18th. The shares were sold at an average price of $196.12, for a total transaction of $724,075.04. Following the sale, the director now owns 28,776 shares of the company’s stock, valued at approximately $5,643,549.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Brian David Archbold sold 392 shares of the company’s stock in a transaction on Tuesday, June 21st. The shares were sold at an average price of $188.22, for a total transaction of $73,782.24. Following the completion of the sale, the senior vice president now directly owns 813 shares in the company, valued at $153,022.86. The disclosure for this sale can be found here. Insiders sold 6,562 shares of company stock worth $1,264,266 in the last 90 days. 5.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a research report on Friday, August 5th.

Mesa Laboratories Company Profile

(Get Rating)

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries.

Recommended Stories

Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLABGet Rating).

Institutional Ownership by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.